Press Alt+1 for screen-reader mode, Alt+0 to cancelAccessibility Screen-Reader Guide, Feedback, and Issue Reporting | New window
timothy sykes logo

Stock News

Inspire Medical Systems Surges After EPS Forecast Boost and Strong Q3 Results

Ellis HobbsAvatar
Written by Ellis Hobbs Reviewed by Jack Kellogg Fact-checked by Tim Sykes
Updated 11/21/2025, 4:14 pm ET | 5 min
Inspire Medical Systems Surges After EPS Forecast Boost and Strong Q3 Results Thumbnail

In this article Last trade Nov, 21 4:20 PM

  • INSP+7.93%
    INSP - NYSEInspire Medical Systems Inc.
    $89.87+6.60 (+7.93%)
    Volume:  1.66M
    Float:  28.39M
    $83.37Day Low/High$90.57

Inspire Medical Systems Inc.’s stocks have been trading up by 7.93% as FDA approvals fuel investor optimism.

Healthcare industry expert:

Analyst sentiment – positive

  1. Market Position & Fundamentals: Inspire Medical Systems (INSP) has solidified its market presence, evidenced by a considerable gross margin of 84.5%, indicating efficient cost management and a robust product offering in the medical device field. The company’s revenue of $802.8 million, with an impressive three-year revenue growth rate of 41.99%, highlights its expanding market share. However, its pre-tax profit margin sits at -2.5%, primarily due to elevated operating expenses and reinvestments. The low debt-to-equity ratio of 0.05 and substantial liquidity (current ratio of 6.1) underscore its financial stability and ability to meet short-term obligations. Such fundamentals position INSP well for further growth if it can enhance cost efficiency to convert high revenue into solid profitability.

  2. Technical Analysis & Trading Strategy: The weekly price data shows an initial decline in the stock prices, followed by a significant surge on November 21, suggesting a potential breakout at the $83 level, moving swiftly to $89.87. This marks a notable bullish reversal with increased buying interest. For traders, the dominant trend postulates a bullish outlook, with the short-term technical levels suggesting strong support around $84, while resistance is closely observed at $90. With the recent uptrend supported by volume uptick, a strategic entry point could be near the support level of $84, targeting gains towards the resistance at $90, while maintaining vigilant oversight on volume dynamics and market conditions.

  3. Catalysts & Outlook: Recent developments showcase Inspire Medical’s promising trajectory, led by its revised full-year EPS projections between $0.90-$1.00, surpassing prior guidance and aligning with consensus. The transition to the Inspire V system, alongside reported substantial Q3 results—revenue of $224.5M—affirms the company’s product strength and market acceptance. A projected $90M to $100M tax benefit will notably enhance EPS, further attracting investor interest. INSP’s growth remains on track with healthcare benchmarks, yet litigation concerns could pose risk. Analysts recognize upside potential, setting a mean price target of $107.81. With operational advancements and financial improvements, the outlook remains bullish with support noted at $84 and resistance around $90.

Candlestick Chart

Weekly Update Nov 17 – Nov 21, 2025: On Friday, November 21, 2025 Inspire Medical Systems Inc. stock [NYSE: INSP] is trending up by 7.93%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview: Robust Performance and Market Momentum

Inspire Medical Systems reported a third-quarter revenue boost, climbing to $224.5M, topping the analyst consensus of $220.4M. The company’s adjusted EPS of $0.38 markedly outshined the expected loss, reinforcing financial resilience and strategic agility. The Inspire V system proved transformative, demonstrating marked enhancements over legacy devices, further supporting top-line growth. These results prompted the company to raise its EPS forecast for 2025, now between $0.90 and $1.00, cementing its buoyant market outlook. A key financial maneuver includes a projected significant income tax benefit, potentially bolstering diluted EPS by $3.00 to $3.30 through the release of valuation allowances on U.S. deferred tax assets. The company’s financial strategy indicates a robust fiscal year ahead.

More Breaking News

The stock prices are reflecting these solid performance metrics, with the share value closing at $89.87 during the latest trading session. The company’s valuation seems poised for further appreciation, driven by strong operational execution and effective use of financial instruments. With those critical improvements, Inspire Medical is demonstrating sustained profitability and commitment to shareholder value, even amidst broader market volatility. Intangible assets maintain their value with a consistent gross margin of 84.5%, further bolstering its market standing. Interest coverage ratios and low total debt to equity illustrate sound fiscal health, fortifying Inspire’s long-term growth sustainability.

Conclusion

Inspire Medical Systems exhibited formidable financial strength in its latest quarter alongside promising prospects into the subsequent fiscal cycle. The company’s strategic measures, including an enhanced EPS outlook and fiscal maneuvers to maximize stakeholder value, reflect robust operational health. Traders appear poised for continuous engagement given the escalating market confidence fueled by Inspire Medical’s financial discipline and innovation-driven performance. As millionaire penny stock trader and teacher Tim Sykes says, “Consistency is key in trading; don’t let emotions dictate your trades.” This principle echoes for traders as the company builds on its current momentum and capitalizes on strategic growth levers, with market observers anticipating sustained shareholder value accretion and dynamic market positioning within the healthcare technology space.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Ellis Hobbs

Trainer and Mentor on Tim Sykes’ Trading Challenge
He teaches webinars on Tim Sykes’ Trading Challenge He treats trading like a business, not a hobby He emphasizes taking small risks — “If you get the process right, money is a forgone conclusion.”
Read More

In this article (YTD Performance)

  • INSP-55.08%
    INSP - NYSEInspire Medical Systems Inc.
    $89.87+6.60 (+7.93%)
    Volume:  1.66M
    Float:  28.39M
    $83.37Day Low/High$90.57

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”

ts swipe photo
Learn The Formula That Has Created Over 50 Millionaires
TRADE LIKE TIM
notification icon
Subscribe to receive notifications